The consensus price target hints at a 467.5% upside potential for Silence Therapeutics (SLN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in ...
SLN, a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported financial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results